Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 10/20 | 0.52 |
| ▸ | CES2 | O00748 | 6/20 | 0.52 |
| ▸ | FAAH | O00519 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27946917 | 0.97 | CES1 (0.50) | CES1CES2FAAHMEN1CYP1A2 | |
| SCHEMBL3631010 | 0.92 | FAAH (0.62) | CES1CES2FAAHMEN1CYP1A2 | |
| SCHEMBL16186191 | 0.90 | FAAH (0.64) | CES1CES2FAAHMEN1CYP1A2 | |
| SCHEMBL9437438 | 0.90 | FAAH (0.64) | CES1CES2FAAHMEN1CYP1A2 | |
| SCHEMBL8898693 | 0.90 | FAAH (0.64) | CES1CES2FAAHMEN1CYP1A2 | |
| SCHEMBL23052919 | 0.90 | FAAH (0.64) | CES1CES2FAAHMEN1CYP1A2 | |
| SCHEMBL8824699 | 0.90 | FAAH (0.64) | CES1CES2FAAHMEN1CYP1A2 | |
| SCHEMBL16186192 | 0.90 | FAAH (0.64) | CES1CES2FAAHMEN1CYP1A2 | |
| SCHEMBL22525240 | 0.90 | FAAH (0.64) | CES1CES2FAAHMEN1CYP1A2 | |
| SCHEMBL13246772 | 0.90 | FAAH (0.64) | CES1CES2FAAHMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704929-B2 | Diaromatic amine derivatives as antioxidants | CHEMTURA CORPORATION (US) | 2010-04-27 | — | — | US | claimed |
| US-20070155633-A1 | Diaromatic amine derivatives as antioxidants | LANXESS SOLUTIONS US INC. | 2007-07-05 | — | — | US | claimed |
| EP-1276804-B1 | LIQUID ANTIOZONANTS AND RUBBER COMPOSITIONS CONTAINING SAME | UNIROYAL CHEM CO INC (US) | 2006-06-14 | — | — | EP | claimed |
| US-20050282878-A1 | Process for the purification of fluconazole | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-12-22 | — | — | US | claimed |
| US-6706216-B1 | REACTION PRODUCT OF CATALYTIC REDUCTIVE ALKYLATION OF P-PHENYLENEDIAMINE OR DERIVATIVE WITH ACETONE AND SECOND CARBONYL COMPOUND | UNIROYAL CHEMICAL COMPANY, INC. | 2004-03-16 | — | — | US | claimed |
| US-6706217-B2 | OBTAINED FROM THE REACTION OF A PARAPHENYLENEDIAMINE COMPOUND WITH ACETONE AND AT LEAST ONE OF KETONES AND ALDEHYDES, USING A REDUCTIVE ALKYLATION CATALYST | UNIROYAL CHEMICAL COMPANY, INC. | 2004-03-16 | — | — | US | claimed |
| EP-1276804-A1 | LIQUID ANTIOZONANTS AND RUBBER COMPOSITIONS CONTAINING SAME | Uniroyal Chemical Company, Inc. (US) | 2003-01-22 | — | — | EP | claimed |
| US-20020061946-A1 | Liquid antiozonants and rubber compositions containing same | ADDIVANT USA, LLC | 2002-05-23 | — | — | US | claimed |
| WO-2001081459-A1 | LIQUID ANTIOZONANTS AND RUBBER COMPOSITIONS CONTAINING SAME | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2001-11-01 | — | — | WO | claimed |
| US-4240983-A | HALOGENATION | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-23 | — | — | US | claimed |
| US-20260132232-A1 | OPHTHALMIC DEVICES | BAUSCH LOMB IRELAND LTD (IE) | 2026-05-14 | — | — | US | disclosed |
| EP-3788084-B1 | OPHTHALMIC DEVICES CONTAINING UV BLOCKER AND METHODS FOR THEIR PREPARATION | BAUSCH & LOMB (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12552883-B2 | Ophthalmic devices | BAUSCH + LOMB IRELAND LIMITED (IE) | 2026-02-17 | — | — | US | disclosed |
| EP-4677398-A1 | CONTACT LENS CONTAINING DEPROTECTED ULTRAVIOLET BLOCKERS | Bausch + Lomb Ireland Limited (IE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4646240-A1 | BIOMEDICAL DEVICES HAVING A SURFACE COATING | Bausch + Lomb Ireland Limited (IE) | 2025-11-12 | — | — | EP | disclosed |
| US-20020061946-A1 | Liquid antiozonants and rubber compositions containing same | ADDIVANT USA, LLC | 2002-05-23 | — | — | US | disclosed |
| WO-2001081459-A1 | LIQUID ANTIOZONANTS AND RUBBER COMPOSITIONS CONTAINING SAME | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2001-11-01 | — | — | WO | disclosed |
| US-4900868-A | Process for producing N,N'-disubstituted paraphenylene diamine mixtures by sequential reductive alkylation | MONSANTO COMPANY (US) | 1990-02-13 | — | — | US | disclosed |
| EP-0084527-A2 | Process for producing paraphenylenediamine mixtures | MONSANTO COMPANY (US) | 1983-07-27 | — | — | EP | disclosed |
| US-4240983-A | HALOGENATION | BAYER AKTIENGESELLSCHAFT (DE) | 1980-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282878-A1 | Process for the purification of fluconazole | ERG28, CYP51A1, MAN2B1 | CES1 1041/4885CES2 811/4885FAAH 3680/4885 |
| US-20260132232-A1 | OPHTHALMIC DEVICES | MYO1G, CRY1, UACA | CES1 1624/4885CES2 3730/4885FAAH 2049/4885 |
| US-20070155633-A1 | Diaromatic amine derivatives as antioxidants | C9, C5, C1S | CES1 1483/4885CES2 1378/4885FAAH 1048/4885 |
| US-12552883-B2 | Ophthalmic devices | ILK, MYLK, SMAD2 | CES1 3213/4885CES2 4234/4885FAAH 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.